Patents by Inventor Wenzhi Tian

Wenzhi Tian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11926675
    Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: March 12, 2024
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo
  • Patent number: 11891449
    Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: February 6, 2024
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen
  • Patent number: 11672859
    Abstract: The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: June 13, 2023
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li
  • Publication number: 20230167194
    Abstract: The present disclosure provides a recombinant fusion protein containing an extracellular Ig-like domain of a signal-regulator protein (SIRP), linked via a linker, to a paratope of an Ig-like anti-HER2 antibody at the N-terminus of a heavy chain or a light chain constituting the paratope. The present disclosure also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over-expression of CD47 and/or HER2.
    Type: Application
    Filed: August 18, 2022
    Publication date: June 1, 2023
    Inventors: Wenzhi TIAN, Song LI
  • Publication number: 20230110702
    Abstract: The present application provides a recombinant fusion protein containing an anti-CD38 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD38 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD38 using the recombinant fusion protein.
    Type: Application
    Filed: February 4, 2022
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN
  • Publication number: 20230112123
    Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Application
    Filed: March 3, 2022
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN, Huiqin GUO
  • Publication number: 20230114491
    Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.
    Type: Application
    Filed: December 6, 2021
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN
  • Publication number: 20230110607
    Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Application
    Filed: March 3, 2022
    Publication date: April 13, 2023
    Inventors: Wenzhi TIAN, Song LI, Dianze CHEN, Huiqin GUO
  • Patent number: 11613584
    Abstract: Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: March 28, 2023
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo
  • Publication number: 20230083670
    Abstract: The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.
    Type: Application
    Filed: October 7, 2021
    Publication date: March 16, 2023
    Inventors: Wenzhi Tian, Song Li
  • Publication number: 20220340664
    Abstract: Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PD-L1, VEGF and Fc receptor simultaneously. Also disclosed are a recombinant antibody containing two recombinant proteins of the disclosure, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of VEGF and/or PD-L1 using the recombinant protein.
    Type: Application
    Filed: May 5, 2022
    Publication date: October 27, 2022
    Inventors: Wenzhi TIAN, Song LI
  • Patent number: 11453724
    Abstract: The present disclosure provides a recombinant fusion protein containing an extracellular Ig-like domain of a signal-regulator protein (SIRP), linked via a linker, to a paratope of an Ig-like anti-HER2 antibody at the N-terminus of a heavy chain or a light chain constituting the paratope. The present disclosure also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over-expression of CD47 and/or HER2.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 27, 2022
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li
  • Patent number: 11407832
    Abstract: Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PD-L1, VEGF and Fc receptor simultaneously. Also disclosed are a recombinant antibody containing two recombinant proteins of the disclosure, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of VEGF and/or PD-L1 using the recombinant protein.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: August 9, 2022
    Assignee: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    Inventors: Wenzhi Tian, Song Li
  • Patent number: 11407841
    Abstract: Provided is a bi-functional fusion protein as well as its preparation method and use. The bi-functional fusion protein is composed of a monoclonal anti-human CD20 antibody linked to a first extracellular domain of human SIRP?. It is shown in in vitro tests that the bi-functional fusion protein is capable of binding to human CD20 and CD47 simultaneously, thus killing CD20+ tumor cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and is also capable of blocking CD47-SIRP? interaction such that macrophages are activated to attack tumor cells. The bi-functional fusion protein has evident anti-tumor activities.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 9, 2022
    Assignee: Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd.
    Inventors: Wenzhi Tian, Song Li
  • Publication number: 20220010031
    Abstract: Provided is a bi-functional fusion protein as well as its preparation method and use. The bi-functional fusion protein is composed of a monoclonal anti-human CD20 antibody linked to a first extracellular domain of human SIRP?. It is shown in in vitro tests that the bi-functional fusion protein is capable of binding to human CD20 and CD47 simultaneously, thus killing CD20+ tumor cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and is also capable of blocking CD47-SIRP? interaction such that macrophages are activated to attack tumor cells, The bi-functional fusion protein has evident anti-tumor activities.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 13, 2022
    Inventors: Wenzhi Tian, Song Li
  • Publication number: 20210388043
    Abstract: The present invention provides a recombinant fusion protein containing a first extracellular Ig-like domain of a signal-regulator protein alpha (SIRP?), linked to an Fc fragment of a human IgG1. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47.
    Type: Application
    Filed: August 26, 2021
    Publication date: December 16, 2021
    Inventors: Wenzhi TIAN, Deqiang JING
  • Publication number: 20210380716
    Abstract: The present disclosure provides a recombinant fusion protein containing an extracellular Ig-like domain of a signal-regulator protein (SIRP), linked via a linker, to a paratope of an Ig-like anti-HER2 antibody at the N-terminus of a heavy chain or a light chain constituting the paratope. The present disclosure also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over-expression of CD47 and/or HER2.
    Type: Application
    Filed: August 20, 2021
    Publication date: December 9, 2021
    Inventors: Wenzhi Tian, Song Li
  • Patent number: 10973878
    Abstract: The present invention provides a recombinant fusion protein containing an anti-PD-L1 antibody, with at least one paratope of the anti-PD-L1 antibody linked via a linker to an extracellular Ig-like domain of a signal-regulator protein (SIRP) at N-terminus of a heavy chain or a light chain, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47 and/or PD-L1 using the recombinant protein.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: April 13, 2021
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) CO., LTD.
    Inventors: Wenzhi Tian, Song Li
  • Publication number: 20210024598
    Abstract: The present invention provides a recombinant fusion protein containing a first extracellular Ig-like domain of a signal-regulator protein alpha (SIRP?), linked to an Fc fragment of a human IgG1. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47.
    Type: Application
    Filed: June 18, 2020
    Publication date: January 28, 2021
    Inventors: Wenzhi TIAN, Deqiang JING
  • Patent number: 10800821
    Abstract: The present invention provides a recombinant fusion protein containing a first extracellular Ig-like domain of a signal-regulator protein alpha (SIRP?), linked to an Fc fragment of a human IgG1. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: October 13, 2020
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) CO., LTD
    Inventors: Wenzhi Tian, Deqiang Jing